Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival
- 1 October 2018
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 74 (4) , 413-419
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerJournal of Clinical Oncology, 2017
- Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi‐institution studyBJU International, 2017
- Radiation with or without Antiandrogen Therapy in Recurrent Prostate CancerNew England Journal of Medicine, 2017
- Predicting survival of men with recurrent prostate cancer after radical prostatectomyEuropean Journal of Cancer, 2016
- Prostate Cancer, Version 1.2016Journal of the National Comprehensive Cancer Network, 2016
- The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)JNCI: Journal of the National Cancer Institute, 2015
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Intermittent versus Continuous Androgen Deprivation in Prostate CancerNew England Journal of Medicine, 2013
- Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical ProstatectomyJournal of Clinical Oncology, 2007
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999